TABLE 2.
Tolerability, safety and survival related to nintedanib
| Patients | 126 |
| Adverse effects | |
| Yes | 89 (71) |
| Diarrhoea | 49 (39) |
| Nausea and vomiting | 31 (25) |
| Weight loss | 31 (25) |
| Abdominal pain | 22 (17) |
| Appetite loss | 11 (9) |
| Hepatotoxicity | 8 (6) |
| Headache | 8 (6) |
| Constipation | 3 (2) |
| Lethargy | 3 (2) |
| Other | 2 (2) |
| None | 37 (29) |
| Nintedanib dose reduction? | |
| Yes | 37 (29) |
| Surviving patients who completed ≥6 months of nintedanib | |
| Yes | 102 (81) |
| No | 24 (19) |
| Surviving patients on nintedanib at 12 months | |
| Yes | 86 (80) |
| No | 22 (20) |
| Survival at 12 months | |
| Alive | 108 (86) |
| Dead | 18 (14) |
Data are presented as n or n (%).